Suga H - Search Results

1

MET Activation by a Macrocyclic Peptide Agonist that Couples to Biological Responses Differently from HGF in a Context-Dependent Manner.

Miao W, Sakai K, Imamura R, Ito K, Suga H, Sakuma T, Yamamoto T, Matsumoto K. Miao W, et al. Among authors: suga h. Int J Mol Sci. 2018 Oct 12;19(10):3141. doi: 10.3390/ijms19103141. Int J Mol Sci. 2018. PMID: 30322054 Free PMC article.

2

In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors.

Hayashi Y, Morimoto J, Suga H. Hayashi Y, et al. Among authors: suga h. ACS Chem Biol. 2012 Mar 16;7(3):607-13. doi: 10.1021/cb200388k. Epub 2012 Jan 24. ACS Chem Biol. 2012. PMID: 22273180

3

Technologies for the synthesis of mRNA-encoding libraries and discovery of bioactive natural product-inspired non-traditional macrocyclic peptides.

Ito K, Passioura T, Suga H. Ito K, et al. Among authors: suga h. Molecules. 2013 Mar 18;18(3):3502-28. doi: 10.3390/molecules18033502. Molecules. 2013. PMID: 23507778 Free PMC article. Review.

4

Protein cocrystallization molecules originating from in vitro selected macrocyclic peptides.

Hipolito CJ, Bashiruddin NK, Suga H. Hipolito CJ, et al. Among authors: suga h. Curr Opin Struct Biol. 2014 Jun;26:24-31. doi: 10.1016/j.sbi.2014.03.001. Epub 2014 Mar 27. Curr Opin Struct Biol. 2014. PMID: 24681557 Review.

5

Artificial human Met agonists based on macrocycle scaffolds.

Ito K, Sakai K, Suzuki Y, Ozawa N, Hatta T, Natsume T, Matsumoto K, Suga H. Ito K, et al. Among authors: suga h. Nat Commun. 2015 Mar 11;6:6373. doi: 10.1038/ncomms7373. Nat Commun. 2015. PMID: 25758345 Free PMC article.

6

In vivo targeting of c-Met using a non-standard macrocyclic peptide in gastric carcinoma.

Hwang DW, Bahng N, Ito K, Ha S, Kim MY, Lee E, Suga H, Lee DS. Hwang DW, et al. Among authors: suga h. Cancer Lett. 2017 Jan 28;385:144-149. doi: 10.1016/j.canlet.2016.10.030. Epub 2016 Oct 31. Cancer Lett. 2017. PMID: 27810404

7

A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets.

Passioura T, Suga H. Passioura T, et al. Among authors: suga h. Chem Commun (Camb). 2017 Feb 7;53(12):1931-1940. doi: 10.1039/c6cc06951g. Chem Commun (Camb). 2017. PMID: 28091672 Review.

8

Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5.

Song X, Lu LY, Passioura T, Suga H. Song X, et al. Among authors: suga h. Org Biomol Chem. 2017 Jun 21;15(24):5155-5160. doi: 10.1039/c7ob00012j. Org Biomol Chem. 2017. PMID: 28574091

9

Strategies for transitioning macrocyclic peptides to cell-permeable drug leads.

Walport LJ, Obexer R, Suga H. Walport LJ, et al. Among authors: suga h. Curr Opin Biotechnol. 2017 Dec;48:242-250. doi: 10.1016/j.copbio.2017.07.007. Epub 2017 Aug 5. Curr Opin Biotechnol. 2017. PMID: 28783603 Review.

10

Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.

Sakurai Y, Mizumura W, Murata M, Hada T, Yamamoto S, Ito K, Iwasaki K, Katoh T, Goto Y, Takagi A, Kohara M, Suga H, Harashima H. Sakurai Y, et al. Among authors: suga h. Mol Pharm. 2017 Oct 2;14(10):3290-3298. doi: 10.1021/acs.molpharmaceut.7b00362. Epub 2017 Aug 25. Mol Pharm. 2017. PMID: 28789523

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,239 results

Search Page

Filters